PRESTIGE CONSUMER HEALTHCARE (PBH) Fundamental Analysis & Valuation
NYSE:PBH • US74112D1019
Current stock price
62.215 USD
-0.56 (-0.9%)
Last:
This PBH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PBH Profitability Analysis
1.1 Basic Checks
- PBH had positive earnings in the past year.
- In the past year PBH had a positive cash flow from operations.
- PBH had positive earnings in 4 of the past 5 years.
- In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of PBH (5.34%) is better than 86.53% of its industry peers.
- With an excellent Return On Equity value of 10.19%, PBH belongs to the best of the industry, outperforming 84.97% of the companies in the same industry.
- The Return On Invested Capital of PBH (7.55%) is better than 85.49% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PBH is below the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.34% | ||
| ROE | 10.19% | ||
| ROIC | 7.55% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- PBH has a Profit Margin of 16.90%. This is amongst the best in the industry. PBH outperforms 89.64% of its industry peers.
- PBH's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 30.34%, PBH belongs to the top of the industry, outperforming 94.30% of the companies in the same industry.
- In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
- PBH's Gross Margin of 56.12% is fine compared to the rest of the industry. PBH outperforms 68.39% of its industry peers.
- In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.34% | ||
| PM (TTM) | 16.9% | ||
| GM | 56.12% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. PBH Health Analysis
2.1 Basic Checks
- PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for PBH has been reduced compared to 1 year ago.
- The number of shares outstanding for PBH has been reduced compared to 5 years ago.
- Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
- PBH has an Altman-Z score of 2.48. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
- PBH has a better Altman-Z score (2.48) than 65.80% of its industry peers.
- The Debt to FCF ratio of PBH is 3.95, which is a good value as it means it would take PBH, 3.95 years of fcf income to pay off all of its debts.
- PBH has a Debt to FCF ratio of 3.95. This is amongst the best in the industry. PBH outperforms 87.05% of its industry peers.
- A Debt/Equity ratio of 0.58 indicates that PBH is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.58, PBH is not doing good in the industry: 64.25% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 3.95 | ||
| Altman-Z | 2.48 |
ROIC/WACC0.85
WACC8.9%
2.3 Liquidity
- PBH has a Current Ratio of 3.11. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of PBH (3.11) is comparable to the rest of the industry.
- A Quick Ratio of 1.93 indicates that PBH should not have too much problems paying its short term obligations.
- PBH has a Quick ratio (1.93) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.11 | ||
| Quick Ratio | 1.93 |
3. PBH Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 6.92% over the past year.
- PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
- The Revenue has decreased by -1.31% in the past year.
- Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
3.2 Future
- Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.28% on average per year.
- PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.71% yearly.
EPS Next Y1.25%
EPS Next 2Y3.42%
EPS Next 3Y3.88%
EPS Next 5Y4.28%
Revenue Next Year-2.54%
Revenue Next 2Y-0.26%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. PBH Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 13.89, the valuation of PBH can be described as correct.
- 87.05% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of PBH to the average of the S&P500 Index (25.54), we can say PBH is valued slightly cheaper.
- Based on the Price/Forward Earnings ratio of 12.84, the valuation of PBH can be described as correct.
- PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 84.46% of the companies in the same industry.
- PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.89 | ||
| Fwd PE | 12.84 |
4.2 Price Multiples
- PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 86.01% of the companies in the same industry.
- 88.60% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.02 | ||
| EV/EBITDA | 10.86 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)11.1
PEG (5Y)1.56
EPS Next 2Y3.42%
EPS Next 3Y3.88%
5. PBH Dividend Analysis
5.1 Amount
- No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PBH Fundamentals: All Metrics, Ratios and Statistics
NYSE:PBH (3/24/2026, 2:23:56 PM)
62.215
-0.56 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)05-06 2026-05-06/bmo
Inst Owners110.56%
Inst Owner Change0.31%
Ins Owners1.33%
Ins Owner Change-0.49%
Market Cap2.94B
Revenue(TTM)1.10B
Net Income(TTM)186.50M
Analysts84
Price Target78.95 (26.9%)
Short Float %5.15%
Short Ratio5.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.91%
Min EPS beat(2)-1.36%
Max EPS beat(2)9.18%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)4
Avg EPS beat(8)-0.63%
EPS beat(12)6
Avg EPS beat(12)-46.73%
EPS beat(16)10
Avg EPS beat(16)-34.55%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)5.55%
Revenue beat(4)2
Avg Revenue beat(4)0.29%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)1.18%
PT rev (3m)-0.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.05%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.38%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-2.24%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.89 | ||
| Fwd PE | 12.84 | ||
| P/S | 2.67 | ||
| P/FCF | 11.02 | ||
| P/OCF | 10.64 | ||
| P/B | 1.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.86 |
EPS(TTM)4.48
EY7.2%
EPS(NY)4.85
Fwd EY7.79%
FCF(TTM)5.65
FCFY9.08%
OCF(TTM)5.85
OCFY9.4%
SpS23.32
BVpS38.66
TBVpS-22.26
PEG (NY)11.1
PEG (5Y)1.56
Graham Number62.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.34% | ||
| ROE | 10.19% | ||
| ROCE | 9.98% | ||
| ROIC | 7.55% | ||
| ROICexc | 7.69% | ||
| ROICexgc | 61.8% | ||
| OM | 30.34% | ||
| PM (TTM) | 16.9% | ||
| GM | 56.12% | ||
| FCFM | 24.21% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score5
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 3.95 | ||
| Debt/EBITDA | 2.88 | ||
| Cap/Depr | 31.31% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 75.79% | ||
| Profit Quality | 143.26% | ||
| Current Ratio | 3.11 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 2.48 |
F-Score5
WACC8.9%
ROIC/WACC0.85
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.25%
EPS Next 2Y3.42%
EPS Next 3Y3.88%
EPS Next 5Y4.28%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.54%
Revenue Next 2Y-0.26%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
EBIT growth 1Y1.3%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year5.29%
EBIT Next 3Y3.49%
EBIT Next 5Y2.82%
FCF growth 1Y15.15%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y14.78%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.25% in the next year.